Fifth Hospital In Wuhan

BackgroundStroke remains the primary source of prolonged disability worldwide since it often results in gait asymmetry. Research shows compensatory mechanisms in chronic stroke patients’ non-paretic legs but lacks knowledge about these adaptations during the early post-stroke period when walking on inclines which mimic real-world mobility challenges.ObjectiveThis study sought to clarify the compensatory strategies in the non-paretic leg of early post-stroke survivors by analyzing the changes in vertical ground reaction force (GRF) profiles and respective variabilities during level (0%) and inclined (6%) treadmill walking, relative to healthy, matched controls.MethodsThe study included fourteen early post-stroke survivors who were three months post-event or less along with fourteen matched controls. Participants walked at their preferred speeds on treadmill at 0% and 6% grade incline settings. Researchers determined key vertical GRF profiles, including peak amplitudes (F1, F2, F3), impulses (J1–J4), timing to each peak, loading/unloading rates, and their respectively variabilities. Mixed two-way repeated measures Analysis of covariance (ANCOVA) were used and preferred walking speed was used as a covariate.ResultsStroke survivors demonstrated significantly slower walking speeds compared to control participants (0.6 km/hr vs. 2.15 km/hr) while both groups shared similar demographic characteristics. It is worth mentioning that this study specifically focused on the non-paretic side; therefore, only GRF components corresponding to the non-paretic leg of the stroke survivors were investigated. During weight acceptance (F1) and push-off (F3) phases, stroke survivors showed lower vertical ground reaction force (VGRF) peak amplitudes (F1- control (C): 1.11 vs. patients (P): 1.04, F3 - C: 1.09 vs. P: 1.03) and impulse magnitudes (J1- C: 25.46 vs. P: 18.74, J2 - C: 21.37 vs. P: 13.46, J3- C: 22.38 vs. P: 15.71, J4 - C: 22.16 vs. P: 18.19) in their non-paretic leg compared to control subjects regardless of inclines. Stroke survivors presented higher F2 (mid-stance, F2 - C: 0.92 vs. P: 0.98) values which might indicate a flatter vertical ground reaction force profile due to compensatory or pathological gait mechanisms. Inclined walking produced increased F1 (Grade 0%: 1.06 vs. Grade 6%: 1.10) and decreased F2 (Grade 0%: 0.97 vs. Grade 6%: 0.93) for both participant groups, but controls exhibited increased F3 (Grade 0%: 1.06 vs. Grade 6%: 1.12) while stroke survivors showed reductions in F3 (Grade 0%: 1.05 vs. Grade 6%: 1.01) which indicated impaired push-off mechanics.ConclusionsThe study demonstrates that treating the non-paretic leg as a healthy limb is inadequate and shows the necessity for rehabilitation approaches that target both legs individually. Focusing on motor control and force steadiness instead of simply strength can more effectively reduce maladaptive variability and enhance safe and efficient walking patterns.

The long-term immune and metabolic effects of COVID-19 in vaccinated populations remain incompletely characterized. This study aimed to analyze dynamic changes in lymphocyte subpopulations (T, B, and Natural Killer [NK] cells [TBNK]) and key metabolic indicators among college students post-Omicron infection with prior vaccination. A prospective observational cohort of 71 male students infected with the Omicron variant of COVID-19 (Beijing, China; March-April 2022) and 18 uninfected controls was followed for 2 years. TBNK subsets and metabolic parameters (uric acid, lipid profiles, β2-microglobulin) were analyzed at 3, 6, 12, and 24 months post-infection. Immunologically, total lymphocytes were elevated at 3 months when compared with controls (P = 0.0063). Total T cells declined at 6 and 12 months but rebounded by 24 months (P < 0.0001). NK cells increased until 12 months, then declined (P < 0.0001). B cells decreased persistently (P < 0.05). Metabolically, uric acid and lipid parameters (total cholesterol, LDL-C, lipoprotein [a]) showed significant fluctuations, with notable increases at 1 year post-infection (P < 0.05). β2-microglobulin levels decreased significantly over time (P < 0.0001). Omicron infection induces immune and metabolic disturbances lasting at least 1 year, with gradual but incomplete recovery by 2 years. The interplay between immune dysregulation and metabolic alterations may contribute to the long-term health effects of COVID-19. Monitoring both lymphocyte and metabolic dynamics may guide the long-term management of post-COVID-19 sequelae.

Albumin-corrected anion gap (ACAG) has emerged as a prognostic biomarker for critically ill patients. The mortality risk in patients with chronic kidney disease (CKD) complicated by sepsis is markedly increased Due to immune dysfunction, chronic inflammation, and metabolic disturbances. This study sought to investigate the associations between ACAG levels and mortality outcomes, including ICU, in-hospital, 14-day, 28-day, and 90-day mortality, in critically ill patients with CKD and sepsis. A total of 3459 critically ill patients with CKD and sepsis who were admitted to the ICU at Beth Israel Deaconess Medical Center were included in the analysis. These patients were categorized into two groups-lower and higher ACAG-based on the determined optimal threshold. Multivariate Cox proportional hazards models were employed to examine the associations between ACAG and ICU mortality, in-hospital mortality, as well as 14-, 28-, and 90-day mortality. The receiver operating characteristic (ROC) curve was used to evaluate the predictive ability, sensitivity, specificity, and area under the curve of ACAG for short-term and long-term mortality after admission in this specific patient population. Additionally, restricted cubic spline (RCS) analysis was conducted to explore the potential dose-response relationship between ACAG and these mortality outcomes. Subgroup analyses were conducted to assess how patient characteristics affect the prognostic value of ACAG. Compared with the lower ACAG group (n = 2482), the higher ACAG group (n = 977) exhibited significantly higher ICU mortality, in-hospital mortality, and 14-, 28-, and 90-day mortality. Multivariate Cox regression analysis revealed that elevated ACAG levels were independently Linked to a higher risk of ICU mortality, in-hospital mortality, as well as 14-, 28-, and 90-day mortality rates. RCS analysis identified significant Linear relationships between ACAG levels and the risk of ICU death, in-hospital mortality, as well as mortality at 14, 28, and 90days. ROC curve analysis indicated that ACAG had superior predictive ability for prognosis in this patient population compared to anion gap. The results of the subgroup analyses indicated that there were no statistically significant interactions between ACAG and most specific patient subgroup. ACAG serves as an independent prognostic marker for critically ill patients suffering from CKD and sepsis. As an easily accessible and cost-effective biomarker, ACAG can aid in the early identification of high-risk patients, optimize patient management, and improve patient outcomes.

QiShenYiQi (QSYQ) has shown promise in the treatment of blood-brain barrier (BBB) damage following stroke. However, the identification of its bioactive components and the underlying molecular mechanisms of action remain unknown. This study aimed to investigate the active ingredients and mechanisms involved in the inhibitory effects of QSYQ on BBB damage after ischemic stroke based on network pharmacology and experimental verification. The chemical composition and target information of QSYQ were obtained from the Traditional Chinese Medicine Systems Pharmacology and Analysis Platform. BBB injury-related targets were identified by screening databases, and the overlapping targets with QSYQ were collected. Cytoscape software was utilized to construct protein-protein interaction (PPI) networks. Molecular docking analysis was conducted using AutoDock software. Animal experiments were carried out to verify the protective effect of QSYQ on BBB and explore potential molecular mechanisms. A total of 131 active ingredients in QSYQ and 154 common targets related to QSYQ and BBB damage were identified. Analysis of the PPI network revealed key targets including ALB, INS, ACTB, TP53, and CASP3 against BBB injury. Molecular docking analysis indicated favorable binding interactions between dihydrotanshinlactone, tanshinone IIA, salviolone, and their respective target proteins, such as FOS, INS, CASP3, and JUN. In animal experiments, QSYQ demonstrated effective inhibition of BBB damage, and this effect may be attributed to the regulation of ALB, INS, TP53, and CASP3. This study provides intriguing insights into the mechanisms by which QSYQ protects against BBB injury following ischemic stroke. Key targets, including ALB, INS, TP53, and CASP3, could be potentially involved in the beneficial effects of QSYQ.